Pembrolizumab Combo Fails to Reach Endpoint in Gastroesophageal Junction Cancer Trial
source: shutterstock.com

Pembrolizumab Combo Fails to Reach Endpoint in Gastroesophageal Junction Cancer Trial

According to a story from Healio, a phase 3 clinical trial evaluating pembrolizumab plus perioperative chemotherapy as a treatment for locally advanced and resectable gastric adenocarcinoma and gastroesophageal junction cancer…

Continue Reading Pembrolizumab Combo Fails to Reach Endpoint in Gastroesophageal Junction Cancer Trial
Study of the Week: Early GI Cancer Screening is Recommended for Primary Immunodeficiency Patients
source: pixabay.com

Study of the Week: Early GI Cancer Screening is Recommended for Primary Immunodeficiency Patients

Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…

Continue Reading Study of the Week: Early GI Cancer Screening is Recommended for Primary Immunodeficiency Patients
FDA Decision on Opdivo with Chemotherapy for Advanced Gastrointestinal Cancers will be Made Next Month
source: pixabay.com

FDA Decision on Opdivo with Chemotherapy for Advanced Gastrointestinal Cancers will be Made Next Month

By May 25th, 2021 the FDA will announce their decision regarding approval of Opdivo used in combination with chemotherapy for gastrointestinal cancers. Back in December, Priority Review was granted to…

Continue Reading FDA Decision on Opdivo with Chemotherapy for Advanced Gastrointestinal Cancers will be Made Next Month
ICYMI: Study Suggests Female Cancer Patients Have Better Outcomes After Treatment, Experience Worse Side Effects
DarkoStojanovic / Pixabay

ICYMI: Study Suggests Female Cancer Patients Have Better Outcomes After Treatment, Experience Worse Side Effects

According to a publication from EurekAlert, a recent study helmed by the Royal Marsden NHS Foundation Trust suggests that female cancer patients tend to live slightly longer following treatment than…

Continue Reading ICYMI: Study Suggests Female Cancer Patients Have Better Outcomes After Treatment, Experience Worse Side Effects
Study Suggests Female Cancer Patients Have Better Outcomes After Treatment, Experience Worse Side Effects
DarkoStojanovic / Pixabay

Study Suggests Female Cancer Patients Have Better Outcomes After Treatment, Experience Worse Side Effects

According to a publication from EurekAlert, a recent study helmed by the Royal Marsden NHS Foundation Trust suggests that female cancer patients tend to live slightly longer following treatment than…

Continue Reading Study Suggests Female Cancer Patients Have Better Outcomes After Treatment, Experience Worse Side Effects

New Treatment Approved by FDA for Rare Form of Hepatocellular Carcinoma

The FDA has just recently approved CYRAMZA as a treatment for those with hepatocellular carcinoma (HCC), who have been treated with sorafenib, and who have ≥400 ng/mL of alpha-fetoprotein (AFP).…

Continue Reading New Treatment Approved by FDA for Rare Form of Hepatocellular Carcinoma